Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals Announces Name Change to KALA BIO
August 02, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 23, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
April 28, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
April 12, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
March 29, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
March 27, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 03, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
December 27, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
November 28, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
November 28, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors
November 01, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Reverse Stock Split
October 20, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 18, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx
June 03, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference
May 27, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 20, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
May 06, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 05, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call
April 28, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright